A study of ETN101 for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests an experimental oral drug (ETN101) for adults with advanced liver cancer (hepatocellular carcinoma) that has gotten worse after standard treatments or can't be treated with standard therapy. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- Your liver cancer is advanced (BCLC stage B or C) and standard treatments either didn't work or can't be used.
- Your liver function is fairly good (Child-Pugh score A, which means the liver is working pretty well).
- You are healthy enough to be up and active for most of the day (ECOG 0 or 1).
- You have at least one measurable liver tumor that hasn't been treated locally (or has grown since treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests TTI-101, by itself and with other cancer medicines, for liver cancer that is advanced and cannot be removed by surgery. It aims to see whether the treatment can slow the cancer down and improve outcomes.
This early-phase trial tests an experimental drug called CD-801 given through an IV for people with advanced liver cancer (HCC) that cannot be surgically removed and has not responded to or is not suitable for standard treatments. The goal is to see if CD-801 is safe and helps shrink tumors.
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
This Phase 1/2 trial tests an immune-cell treatment (ET140203 T cells) in children and teens with certain liver cancers that have come back or did not respond to standard treatment. It aims to see whether these T cells can shrink tumors and is mainly focused on safety and early effectiveness.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.